← Human Trials & Peer-Reviewed Studies
Prolonged effect of CGRP in Raynaud's patients: a double-blind randomised comparison with prostacyclin
Plain-language guide to PMID 1931469 (1991): double-blind randomized controlled trial study of CGRP (Calcitonin Gene-Related Peptide), raynaud's.
Key Facts
- PMID
- 1931469
- Journal
- British journal of clinical pharmacology
- Year
- 1991
- Study type
- Randomized Controlled Trial
- Authors
- Shawket S et al. (4 authors)
- DOI
- 10.1111/j.1365-2125.1991.tb03883.x
What This Study Did, in Plain Language
What Was Tested
The paper reports a study of CGRP (Calcitonin Gene-Related Peptide) in the context of raynaud's, published as a randomized controlled trial.
The researchers have now investigated whether long infusion of CGRP can relieve symptoms of patients with Raynaud's disease using prostacyclin as a control. 3.
In addition to blood pressure, heart rate and skin blood flow measurements, infrared thermography and cold stress challenge was performed before, immediately after infusion and at 3 and 14 days post-infusion. 5.
Who Took Part
PubMed indexes the participants as adults and middle-aged adults, women only.
Six patients were randomised to receive intravenous infusion of either human alpha-CGRP on one occasion, or prostacyclin (PGI2) on another occasion in a double-blind and cross-over design.
How the Study Was Run
The researchers set it up as a randomized, double-blind and crossover study.
Because people in this CGRP (Calcitonin Gene-Related Peptide) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.
Neither the participants nor the staff measuring them knew who was on CGRP (Calcitonin Gene-Related Peptide), so expectations could not easily colour the readings.
In the crossover set-up each of the participants took both CGRP (Calcitonin Gene-Related Peptide) and the comparison in turn, acting as their own control.
What Was Measured
In addition to blood pressure, heart rate and skin blood flow measurements, infrared thermography and cold stress challenge was performed before, immediately after infusion and at 3 and 14 days post-infusion. 5.
The subject headings attached to it are Blood Pressure, Body Temperature, Calcitonin Gene-Related Peptide, Cold Temperature, Epoprostenol, Flushing and Heart Rate.
What This Means in Plain Language
The paper is a randomized, double-blind and crossover study of CGRP (Calcitonin Gene-Related Peptide) in people with raynaud's.
The publication is from 1991 (British journal of clinical pharmacology), a journal based in England.
More context: the CGRP (Calcitonin Gene-Related Peptide) compound page, Raynaud's research.
Our Notes on the Compound
CGRP (Calcitonin Gene-Related Peptide): A 37-amino-acid neuropeptide that widens blood vessels and is involved in migraine; given in research provocation studies.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.